公开(公告)号：US20210403950A1

公开(公告)日：2021-12-30

申请号：US17293153

申请日：2019-11-13

Applicant: ONCORUS, INC.

Inventor： Mitchell H. FINER ,  Edward KENNEDY ,  Lorena LERNER

IPC: C12N15/86 ,  A61K9/51 ,  A61K35/768 ,  A61P35/00

Abstract: The present disclosure relates to polynucleotides comprising a nucleic acid sequence encoding a replication competent viral genome, wherein the polynucleotide is capable of producing a replication competent virus when introduced into a cell by a non-viral delivery vehicle. The present disclosure further relates to the encapsulation of the polynucleotides and the use of the polynucleotides and/or particles for the treatment and prevention of cancer.

公开(公告)号：US20200206285A1

公开(公告)日：2020-07-02

申请号：US16633653

申请日：2018-07-26

Applicant: ONCORUS, INC.

Inventor： Mitchell H. FINER ,  Lorena LERNER ,  Christophe QUÉVA ,  Edward KENNEDY

IPC: A61K35/763 ,  C12N7/00 ,  C12N15/86

Abstract: The present disclosure relates to recombinant viral vectors for the treatment and prevention of cancer. Oncolytic viral vectors incorporate one or more of the following features: viral replication restriction by insertion of microRNA (miRNA) target sequences into the viral genome; disruption of oncogenic miRNA function; cancer microenvironment remodeling; and cancer cell targeting by incorporation of protease-activated antibodies into the viral particle.

公开(公告)号：US20230241140A1

公开(公告)日：2023-08-03

申请号：US18165770

申请日：2023-02-07

Applicant: Oncorus, Inc.

Inventor： Mitchell H. FINER ,  Lorena LERNER ,  Christophe QUÉVA ,  Edward KENNEDY

IPC: A61K35/763 ,  C12N7/00 ,  C12N15/86

CPC classification number: A61K35/763 ,  C12N7/00 ,  C12N15/86 ,  C12N2710/16632 ,  C12N2710/16643

Abstract: Oncolytic viral vectors that incorporate one or more of the following features: viral replication restriction by insertion of microRNA (miRNA) target sequences into the viral genome; disruption of oncogenic miRNA function; cancer microenvironment remodeling; and cancer cell targeting by incorporation of protease-activated antibodies into the viral particle. Such viral vectors can be used for the treatment and prevention of cancer.